Icahn School of Medicine at Mount Sinai

Company

Related News

Myeloma Immunotherapies Show Promise, but Access Barriers Persist

Multiple myeloma immunotherapies like bispecific antibodies and CAR-T cells show high response rates and prolonged survival, but access is hindered by the need for initial hospital stays for bispecifics. Research indicates mezigdomide can reverse T cell exhaustion to boost these therapies, while longer-term CARVYKTI data show significant survival benefits.

Related Clinical Trials

NCT ID Title Status Phase
NCT07748377

Increasing Breast and Colorectal Cancer Screening in the Community

NOT_YET_RECRUITING NA
NCT07747116

Knee Positioning After Total Knee Replacement

NOT_YET_RECRUITING NA
NCT07745374

Safety and Feasibility of DBS for Bipolar Depression

RECRUITING NA
NCT07734090

Natural History of MADD

NOT_YET_RECRUITING
NCT07730853

Isocaloric Navy-Bean Substitution in Adults With MASLD

NOT_YET_RECRUITING NA
NCT07714343

Recover@Home Postoperative Follow-up Study

NOT_YET_RECRUITING NA
NCT07695909

Gestational Changes in Hemodynamics and Respiratory Mechanics in Association With Pre-Eclampsia

NOT_YET_RECRUITING
NCT07680140

Biomarker-Guided Antidepressant Selection

NOT_YET_RECRUITING PHASE4
NCT07675044

Quantifying the Burden of Type 2 (T2) Inflammation in Asthma

NOT_YET_RECRUITING
NCT07671599

Perioperative Use of Continuous Glucose Monitoring for Scheduled Cesarean Deliveries (PERUSE)

NOT_YET_RECRUITING